Literature DB >> 2089250

Severe hypophosphatemia in hospitalized patients.

M A Camp1, M Allon.   

Abstract

Although severe hypophosphatemia has been associated with significant morbidity, little quantitative information is available on the magnitude of the risk. The objective of this study was to determine the frequency and timing of severe hypophosphatemia, the relative risk associated with various medical diagnoses, and the choice of therapy. Among 10,197 patients hospitalized over a 1-year period, the incidence of severe hypophosphatemia (serum phosphate less than or equal to 0.33 mmol/l) was 0.43%. The incidence was 0.91% in alcoholics, 2.42% in septic patients, 10.4% in patients with malnutrition, and 14.6% in patients with diabetic ketoacidosis. The odds ratio for developing the metabolic abnormality was 4.2 (95% confidence interval 2.2-8.1) in alcoholics, 6.4 (1.9-18.9) in septic patients, 46.9 (16.6-125.6) in patients with diabetic ketoacidosis, and 60.7 (31.4-117.5) in malnourished patients. There was a 4-fold increase in mortality in patients with severe hypophosphatemia (18.2 vs. 4.6%; p less than 0.001). The metabolic abnormality was not recognized or was inappropriately treated in 42% of patients. Severe hypophosphatemia is a relatively common finding in hospitalized patients, especially in those with certain well-defined medical conditions. It is associated with significant excess mortality. Its recognition and treatment remain suboptimal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2089250

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  13 in total

Review 1.  Refeeding syndrome: what it is, and how to prevent and treat it.

Authors:  Hisham M Mehanna; Jamil Moledina; Jane Travis
Journal:  BMJ       Date:  2008-06-28

Review 2.  Refeeding syndrome : physiological background and practical management.

Authors:  Aminda De Silva; Jeremy M D Nightingale
Journal:  Frontline Gastroenterol       Date:  2019-12-30

3.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

4.  Association of Phosphate-Containing versus Phosphate-Free Solutions on Ventilator Days in Patients Requiring Continuous Kidney Replacement Therapy.

Authors:  Melissa L Thompson Bastin; Arnold J Stromberg; Sethabhisha N Nerusu; Lucas J Liu; Kirby P Mayer; Kathleen D Liu; Sean M Bagshaw; Ron Wald; Peter E Morris; Javier A Neyra
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-27       Impact factor: 10.614

Review 5.  Treatment of hypophosphatemia in the intensive care unit: a review.

Authors:  Daniël A Geerse; Alexander J Bindels; Michael A Kuiper; Arnout N Roos; Peter E Spronk; Marcus J Schultz
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

Review 6.  Refeeding Syndrome in the Critically Ill: a Literature Review and Clinician's Guide.

Authors:  C L McKnight; C Newberry; M Sarav; R Martindale; R Hurt; B Daley
Journal:  Curr Gastroenterol Rep       Date:  2019-11-22

7.  A comparison of two different refeeding protocols and its effect on hand grip strength and refeeding syndrome: a randomized controlled clinical trial.

Authors:  Sissel Urke Olsen; Karin Hesseberg; Anne-Marie Aas; Are Hugo Pripp; Anette Hylen Ranhoff; Asta Bye
Journal:  Eur Geriatr Med       Date:  2021-06-04       Impact factor: 1.710

Review 8.  Refeeding syndrome--awareness, prevention and management.

Authors:  Hisham Mehanna; Paul C Nankivell; Jamil Moledina; Jane Travis
Journal:  Head Neck Oncol       Date:  2009-01-26

9.  Hyperphosphatemia Is an Independent Risk Factor for Mortality in Critically Ill Patients: Results from a Cross-Sectional Study.

Authors:  Dominik G Haider; Gregor Lindner; Michael Wolzt; Sufian S Ahmad; Thomas Sauter; Alexander Benedikt Leichtle; Georg-Martin Fiedler; Valentin Fuhrmann; Aristomenis K Exadaktylos
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

10.  Hypophosphatemia promotes lower rates of muscle ATP synthesis.

Authors:  Dominik H Pesta; Dimitrios N Tsirigotis; Douglas E Befroy; Daniel Caballero; Michael J Jurczak; Yasmeen Rahimi; Gary W Cline; Sylvie Dufour; Andreas L Birkenfeld; Douglas L Rothman; Thomas O Carpenter; Karl Insogna; Kitt Falk Petersen; Clemens Bergwitz; Gerald I Shulman
Journal:  FASEB J       Date:  2016-06-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.